NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin

Location

United Kingdom: ITT lists participating authorities

Description

NHS Framework Agreement for Human Albumin & Normal and Anti-D ImmunoglobulinOffer reference number: CM/PHS/23/5703The period of the framework is 1 April 2025 to 31 December 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 15 months. The total maximum framework agreement duration, including extension options, will be no more than 48 months. NHS Framework Agreement for Human Albumin & Normal and Anti-D ImmunoglobulinOffer reference number: CM/PHS/23/5703Period of framework agreement: 1 April 2025 to 31 December 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 15 months. The total maximum framework agreement duration, including extension options, will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.

Lot Division

Award Detail

Award Criteria

CPV Codes

• 33651520 - Immunoglobulins

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. ** Out of the awarded suppliers, they were either awarded a committed market share or designated as reserve status with no committed market share. Further information on committed or reserve status by Lot is shown below:Lot 1Awarded Supplier - CSL, GrifolsReserve Supplier - OctapharmaLot 2Awarded Supplier - OctapharmaReserve Supplier - Grifols, TakedaLot 3Awarded Supplier - Grifols, Octapharma, TakedaReserve Supplier - BPL, CSL, LFBLot 4Awarded Supplier - Grifols, Octapharma, TakedaReserve Supplier - CSLLot 5Awarded Supplier - TakedaReserve Supplier – N/ALot 6 Awarded Supplier - CSLReserve Supplier - BPL